Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Revelation Biosciences, Inc. Announces Financial Results for the three and six months ended June 30, 2025
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split effective July 7, 2025
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
Gemini priming attenuates inflammation in human peripheral blood mononuclear cells
Revelation Biosciences to host Fireside Chat at 37th Annual Roth Conference
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
Revelation Biosciences doses first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split effective January 28, 2025
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
